Examining Key Data from DAREON-8

EP: 1.Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer

EP: 2.ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC

EP: 3.cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

EP: 4.Examining 3-Year Update Data from the CASPIAN Trial

EP: 5.Predictors of Immunotherapy Response in Limited and Extensive SCLC

EP: 6.Overcoming Immunotherapy Resistance in Small Cell Lung Cancer

EP: 7.Examining the use of PD-L1 and tTMB in the CASPIAN Trial

EP: 8.Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy

EP: 9.Navigating Later-Line Therapy Sequencing in LS-SCLC Progression

EP: 10.DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

EP: 11.Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC

Now Viewing

EP: 12.Examining Key Data from DAREON-8

EP: 13.Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

Video content above is prompted by the following questions:

1. DAREON-8: Phase 1 Clinical Trial of Combination Therapy with BI 764532, a DLL3 Targeting T-Cell Engager
   1. Please share your opinions of the therapeutic potential of Bl 764532, an lgG-like T-cell engager, for its ability to induce selective T-cell mediated tumor cell lysis when added to SOC (carboplatin + etoposide + atezolizumab) for previously untreated patients with ES-SCLC:
   2. Is a commercial molecular assay currently available to identify the presence of the delta-like ligand 3 notch receptor in patients with SCLC?
   3. Are you encouraged by an overall response rate of 28% and a 54% disease control rate in the Phase I trial?
   4. For which line of therapy do you envision BI 764532, if approved?
   5. Based on the exclusion criteria for the dose escalation trial, are you concerned that this agent may be associated with cardiovascular, cerebrovascular, and/or immunosuppressive TRAEs?